Thor Medical

Equities

NANOV

NO0010597883

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-26 am EDT			5-day change	1st Jan Change
1.08 ^NOK	+1.89%		+1.31%	-16.28%

Feb. 28	Transcript : Thor Medical ASA, H2 2023 Earnings Call, Feb 28, 2024
Feb. 14	Thor Medical ASA Announces CEO Changes	CI

Nordic Nanovector ASA Announces CEO Changes

January 31, 2023 at 05:15 pm EST

Nordic Nanovector ASA announced that Ludvik Sandnes, former Chairperson of Nordic Nanovector, has been appointed interim Chief Executive Officer (CEO) of the Company as from 1 February 2023. Ludvik Sandnes will no more attend the Oncoinvent Board. Malene Brondberg, current interim CEO, will transition out of the Company, as previously announced on 9 December 2022.

Latest news about Thor Medical

Transcript : Thor Medical ASA, H2 2023 Earnings Call, Feb 28, 2024	Feb. 28
Thor Medical ASA Announces CEO Changes	Feb. 14	CI
Thor Medical ASA Appoints Alf Bjørseth as Senior Vice President & Strategic Advisor	Feb. 14	CI
Thor Medical ASA Signs LOI for Offtake with US and Scandinavian Clinical Trial Stage Companies	Nov. 15	CI
Thor Medical Signs Deal to Supply Alpha Emitters; Shares Surge	Nov. 15	MT
Transcript : Thor Medical ASA, H1 2023 Earnings Call, Aug 31, 2023	23-08-31
Nordic Nanovector Concludes Purchase of Thor Medical	23-07-04	MT
Nordic Nanovector ASA Appoints Brede EllingsÃ¦ter as CFO	23-07-03	CI
Thor Medical As completed the acquisition of Nordic Nanovector ASA (OB:NANOV) from North Energy ASA (OB:NORTH), Jon Magne Asmyr, Roy H. Larsen and Ludvik Sandnes and others in a reverse merger transaction.	23-07-02	CI
Nordic Nanovector ASA Appoints Alf BjÃ¸rnseth as New Chief Executive Officer	23-06-28	CI
Nordic Nanovector ASA Approves the Appointment of Ludvik Sandnes as New Chairman	23-06-28	CI
Nordic Nanovector ASA Announces Resignation of Jostein Dahle, Chief Scientific Officer and Co-Founder	23-06-22	CI
Transcript : Nordic Nanovector ASA, Thor Medical As - M&A Call	23-06-07
Nordic Nanovector to Buy Radionuclides Producer Thor Medical	23-06-07	MT
Nordic Nanovector Asa Announces Full Results from Phase 2 Clinical Trials of Betalutin®? (177Lu Lilotomab Satetraxetan) in Resistant/Refractory (R) Indolent Non-Hodgkin's Lodgkin's Lhl)	23-04-18	CI
Transcript : Nordic Nanovector ASA, H2 2022 Earnings Call, Feb 28, 2023	23-02-28
Nordic Nanovector Names Ex-Chairperson as Interim CEO/CFO	23-01-31	MT
Nordic Nanovector ASA Announces CFO Changes	23-01-31	CI
Nordic Nanovector ASA Announces CEO Changes	23-01-31	CI
Certain Shares of Nordic Nanovector ASA are subject to a Lock-Up Agreement Ending on 21-JAN-2023.	23-01-20	CI
Nordic Nanovector ASA Announces Resignation of Eddie Berglund from the Board Effect from January 19, 2023	23-01-19	CI
Nordic Nanovector ASA Approves Board Changes	23-01-03	CI
Nordic Nanovector ASA (OB:NANOV) cancelled the acquisition of APIM Therapeutics AS from Sarsia Seed AS, Trond Mohn Stiftelsen, Norsk Innovasjonskapital III Fund, and Investinor Direkte AS.	22-11-30	CI
Transcript : APIM Therapeutics AS, Nordic Nanovector ASA - M&A Call	22-11-24
Nordic Nanovector Board Reiterates Support for Proposed Merger with APIM	22-11-21	MT

Chart Thor Medical

Duration

Period

More charts

Company Profile

Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The Company is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-08-29 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THOR MEDICAL	-16.28%	22.97M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs